ANALYSIS: Minority shareholders in NZX-listed Millennium & Copthorne have an awkward decision to make.
ANALYSIS: Comments from the biotech’s biggest – and soon to be ex – customer reveal a different perspective on its clinical research.
ANALYSIS: Allowing KiwiSaver funds greater exposure to private assets will be good for fund managers. The benefits for investors are more dubious.
ANALYSIS: The solar system provider’s failure could taint its managers and investors, particularly BlackRock.
ANALYSIS: A glimpse into the venture capital investor’s financials reveals some pros and cons.
ANALYSIS: As Vital Healthcare revives a restructuring scheme, directors of its external manager seem particularly antsy about their independence.
ANALYSIS: Alliance Group, the last 100% farmer-owned red meat co-op, needs at least $150m. Don’t bet on farmers stumping up.
ANALYSIS: Its trademark apple business has had a tough few years but Scales’ long-term strategy is gaining traction.
ANALYSIS: The telco's $305m on-market share buyback signalled poor decision-making.
Statutory management has its uses in dealing with dodgy corporates, but it lacks transparency and accountability.
